The Scientist Logo_white
WHITE PAPER

mRNA Vaccines: The Future of Medicine

How researchers develop mRNA vaccines in record time.

 


Agilent_Logo_RGB (1)

 

 

 

473x300_Laptop

The breakthrough in vitro transcribed (IVT) RNA technology that researchers used during the COVID-19 pandemic paved the way for mRNA vaccine development to treat other infectious diseases. During IVT vaccine production, researchers generate synthetic pathogen genome sequences in bulk. In this process, employing robust nucleic acid quality control testing is critical to check the purity and integrity of the final vaccine product.

Download this white paper from Agilent to learn about the history of vaccine development, milestones in mRNA research, and the role of electrophoresis systems in mRNA vaccine development.

For Research Use Only. Not for use in diagnostic procedures.
   

The Scientist c/o LabX Media Group
1000 N West Street, Suite 1200, Wilmington, Delaware, United States, 19801
Toll Free: 888.788.0328 | Phone: 705.528.6888
Email: privacy@the-scientist.com

Privacy Policy

© 1986-2022  The Scientist
 
The Scientist Logo_white

The Scientist needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.